(Q37982013)

26 August 2017

title

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab (English)

1 reference

progressive multifocal leukoencephalopathy

26 August 2017

main subject

0 references

patient

0 references

author

Per Soelberg Sørensen

1

object named as

Per Soelberg Sørensen

1 reference

26 August 2017

Antonio Bertolotto

2

0 references

Eva Havrdová

object named as

Eva Havrdova

6

0 references

Bernd C Kieseier

8

object named as

Bernd C Kieseier

1 reference

26 August 2017

7

Ludwig Kappos

1 reference

26 August 2017

4

Gavin Giovannoni

1 reference

26 August 2017

5

Ralf Gold

1 reference

26 August 2017

Gilles Edan

3

1 reference

26 August 2017

Xavier Montalban

9

1 reference

26 August 2017

Tomas Olsson

10

1 reference

26 August 2017

publication date

1 February 2012

1 reference

Multiple Sclerosis Journal

26 August 2017

published in

1 reference

26 August 2017

volume

18

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

143-152

1 reference

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Progressive multifocal leukoencephalopathy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Seroepidemiology of human polyomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Characterization of JC human polyomavirus infection in a Portuguese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Persistence of DNA Sequences of BK Virus and JC Virus in Normal Human Tissues and in Diseased Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Discrepant findings in immune responses to JC virus in patients receiving natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Progressive multifocal leukoencephalopathy after natalizumab monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

Quantitative risk-benefit analysis of natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511435105

21 January 2018

Identifiers

DOI

10.1177/1352458511435105

1 reference

release_tmhacctfyvevbomeirmzluqed4

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tmhacctfyvevbomeirmzluqed4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference